GSK-25

Overview

GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor ( IC 50 =7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC 50 =398 nM, p70S6K: IC 50 =1 μM). GSK-25 inhibits P450 profile (IC 50 s of 2.5, 5.2, 2.5 µM for CYP2C9 , CYP2D6 , CYP3A4 , respectively).

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > ROCK | Products > Signaling Pathways > Ribosomal S6 Kinase (RSK)

Product Information

• Catalog No.: HY-14362
• CAS No.: 874119-56-9
• Molecular Formula: C24H16Cl2F2N6O
• Molecular Weight: 513.33
• Purity: 98.33%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.75 mg/mL (5.36 mM); Clear solution
• Availability: In-stock

Source

Original product source